Product image of Methox-F (Methotrexate) supplied by GNH India

Methox-F

Active Ingredient:
Methotrexate
Origin:
EU

Methox-F (Methotrexate)

Methotrexate, the active ingredient in Methox-F, is an antimetabolite presented as a subcutaneous injection for subcutaneous use. It is approved in the European Union for adult patients with rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia and non‑Hodgkin lymphoma, where it helps control disease activity and limit abnormal cell growth.

GNH India supplies Methox-F as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Faran S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methotrexate is used across several autoimmune and oncologic disease pathways.

  • Rheumatoid arthritis: reduces joint inflammation and slows structural damage.
  • Psoriasis: diminishes skin plaque formation and severity.
  • Acute lymphoblastic leukemia: interferes with malignant lymphoblast proliferation.
  • Non‑Hodgkin lymphoma: impedes growth of malignant lymphoid cells.

How It Works

  • Methotrexate inhibits the enzyme dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate. This blockade reduces the availability of reduced folate cofactors required for thymidylate and purine synthesis, leading to impaired DNA replication and cell division, particularly in rapidly proliferating immune and cancer cells.

Side Effects

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset occurring shortly after administration.
  • Fatigue: persistent tiredness not relieved by rest.
  • Oral mucositis: painful sores or ulceration of the mouth lining.
  • Cytopenias: reduced white blood cells, red blood cells, or platelets.
  • Elevated liver enzymes: indication of hepatic stress.
  • Alopecia: temporary hair thinning or loss.

Serious or Rare Side Effects

  • Severe hepatotoxicity: potential liver fibrosis or cirrhosis.
  • Pulmonary toxicity: interstitial pneumonitis or fibrosis.
  • Life‑threatening infections: due to profound immunosuppression.
  • Bone marrow aplasia: marked suppression of blood cell production.
  • Renal failure: impaired kidney function, especially with high doses.
  • Secondary malignancies: rare emergence of new cancers.

Precautions & Warnings

Methox-F requires careful monitoring to minimize risks.

  • Liver function monitoring: perform baseline and periodic liver enzyme tests.
  • Hematologic surveillance: regularly check complete blood counts.
  • Renal function assessment: evaluate serum creatinine and clearance before and during therapy.
  • Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception.
  • Concomitant drug review: avoid use with known hepatotoxic or nephrotoxic agents.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methotrexate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity.
  • Penicillins and sulfonamides: may enhance hematologic suppression.
  • Live vaccines: risk of severe infection due to immunosuppression.
  • Alcohol: potentiates hepatic injury.
  • High‑dose folate antagonists: exacerbate cytotoxic effects.

Moderate Interactions (Monitor Closely)

  • Proton pump inhibitors: may affect renal clearance.
  • Diuretics (especially thiazides): increase serum methotrexate levels.
  • Azathioprine: additive bone‑marrow suppression.
  • Warfarin: potential for altered anticoagulation.
  • Trimethoprim: may raise methotrexate concentrations.

Frequently Asked Questions

Methox-F contains methotrexate, which is prescribed for adult patients with rheumatoid arthritis, moderate to severe plaque psoriasis, acute lymphoblastic leukemia, and non‑Hodgkin lymphoma. In each case the drug works to reduce abnormal cell growth or immune‑mediated inflammation.

Methotrexate blocks dihydrofolate reductase, an enzyme needed to regenerate tetrahydrofolate. Without this cofactor, DNA and RNA synthesis are limited, especially in rapidly dividing cells such as immune cells and cancer cells, leading to reduced proliferation.

The dose of Methox-F is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Only a qualified health professional should determine the appropriate regimen.

Methox-F is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. It is also not recommended while breastfeeding, as methotrexate can be excreted in milk and affect the infant.

To request Methox-F, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methox-F (methotrexate) is a first‑line antimetabolite widely used for both autoimmune diseases and certain cancers. Compared with newer agents such as biologic DMARDs, methotrexate is less costly but may require more laboratory monitoring. In oncology, it is often combined with other chemotherapeutics for synergistic effect.

Methox-F should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Maintaining the cold chain preserves drug stability and potency.

Methox-F is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique and the prescriber’s dosing instructions.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, renal failure, and rare secondary malignancies. Patients should be monitored regularly for signs of organ dysfunction and infection.

Methox-F is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic or renal impairment, and those with active, uncontrolled infections. It should also be avoided in patients receiving live vaccines.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT